X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5808) 5808
Book Chapter (5) 5
Conference Proceeding (3) 3
Government Document (3) 3
Magazine Article (2) 2
Publication (2) 2
Book / eBook (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5055) 5055
science & technology (4966) 4966
life sciences & biomedicine (4008) 4008
female (3540) 3540
oncology (2755) 2755
breast cancer (2134) 2134
animals (2067) 2067
receptor, erbb-2 - metabolism (1869) 1869
receptor, erbb-2 - immunology (1818) 1818
cancer (1683) 1683
mice (1565) 1565
middle aged (1362) 1362
cell line, tumor (1333) 1333
breast neoplasms - pathology (1331) 1331
erbb-2 protein (1258) 1258
receptor, erbb-2 - genetics (1225) 1225
tumors (1168) 1168
adult (1093) 1093
aged (1049) 1049
breast neoplasms - metabolism (1032) 1032
research article (947) 947
science & technology - other topics (942) 942
immunohistochemistry (934) 934
trastuzumab (927) 927
medicine (917) 917
multidisciplinary sciences (899) 899
breast neoplasms - drug therapy (863) 863
prognosis (857) 857
immunology (835) 835
epidermal growth factor (820) 820
gene expression (802) 802
research (787) 787
science (777) 777
breast neoplasms - genetics (761) 761
male (725) 725
proteins (703) 703
breast neoplasms - immunology (689) 689
analysis (677) 677
pathology (671) 671
kinases (659) 659
cell biology (657) 657
metastasis (629) 629
signal transduction (617) 617
skin and connective tissue diseases (586) 586
care and treatment (569) 569
her2 (564) 564
chemotherapy (552) 552
health aspects (546) 546
cancer therapies (540) 540
biochemistry & molecular biology (536) 536
genetic aspects (519) 519
patients (503) 503
immunotherapy (499) 499
aged, 80 and over (494) 494
tumor cells, cultured (486) 486
antineoplastic agents - therapeutic use (476) 476
gene expression regulation, neoplastic (475) 475
antibodies, monoclonal, humanized (473) 473
antibodies, monoclonal - therapeutic use (472) 472
medical prognosis (471) 471
mutation (455) 455
mice, inbred balb c (452) 452
receptor, erbb-2 - antagonists & inhibitors (452) 452
medicine, research & experimental (444) 444
research & experimental medicine (444) 444
cancer research (409) 409
apoptosis (399) 399
epidermal growth factor receptors (395) 395
medicine & public health (395) 395
receptor, erbb-2 - analysis (388) 388
antibodies, monoclonal - immunology (387) 387
antineoplastic agents - pharmacology (380) 380
neoplasm staging (371) 371
metastases (368) 368
cell proliferation (365) 365
medical research (362) 362
biology (361) 361
receptors, estrogen - metabolism (356) 356
treatment outcome (353) 353
mice, nude (351) 351
phosphorylation (348) 348
breast neoplasms - therapy (345) 345
receptor, erbb-2 - biosynthesis (342) 342
antibodies (341) 341
biomarkers, tumor - metabolism (338) 338
xenograft model antitumor assays (336) 336
studies (329) 329
cancers and neoplasms (321) 321
receptor, epidermal growth factor - metabolism (317) 317
biomarkers (309) 309
flow cytometry (296) 296
gene amplification (296) 296
monoclonal antibodies (288) 288
receptors (288) 288
breast neoplasms - mortality (285) 285
genes (285) 285
biochemistry (282) 282
mice, transgenic (281) 281
neoplasms (281) 281
antibodies, monoclonal - pharmacology (278) 278
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5746) 5746
Japanese (64) 64
Chinese (56) 56
French (17) 17
German (8) 8
Spanish (7) 7
Russian (5) 5
Hungarian (4) 4
Italian (3) 3
Norwegian (3) 3
Portuguese (3) 3
Polish (2) 2
Danish (1) 1
Finnish (1) 1
Korean (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2011, Volume 108, Issue 17, pp. 7142 - 7147
Trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor-2 (HER2/ErbB-2... 
T lymphocytes | Inoculation | Medical treatment | Antibodies | Cytotoxicity | Breast cancer | Adaptive immunity | Natural killer cells | Tumors | Cancer | Natural killer cell | Innate | Adaptive | Tumor immunology | Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Receptor, ErbB-2 - genetics | Receptors, Interleukin-1 Type I - immunology | CD8-Positive T-Lymphocytes - transplantation | Humans | Receptors, Interleukin-17 - immunology | Receptors, Interleukin-17 - genetics | Tumor Necrosis Factor Receptor Superfamily, Member 9 - genetics | Adoptive Transfer | Interferon Type I - immunology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Antibodies, Monoclonal, Humanized | Receptor, ErbB-2 - immunology | Interferon-gamma - genetics | Antibodies, Monoclonal - immunology | Mammary Neoplasms, Animal - genetics | Mammary Neoplasms, Animal - immunology | Antibodies, Monoclonal - pharmacology | Tumor Necrosis Factor Receptor Superfamily, Member 9 - immunology | Mice, Transgenic | Antineoplastic Combined Chemotherapy Protocols - immunology | Mice, SCID | Animals | Apoptosis Regulatory Proteins | Interferon-gamma - immunology | Receptors, Interleukin-1 Type I - genetics | Cell Line, Tumor | Interferon Type I - genetics | Programmed Cell Death 1 Receptor | Antigens, Surface | Mammary Neoplasms, Animal - drug therapy | Mice | Mice, Inbred BALB C | CD8-Positive T-Lymphocytes - immunology | Trastuzumab | Biological Sciences | adaptive | tumor immunology | natural killer cell | innate
Journal Article
Oncogene, ISSN 0950-9232, 08/2008, Volume 27, Issue 37, pp. 5019 - 5032
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 11/2009, Volume 27, Issue 33, pp. 5538 - 5546
Purpose Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
PloS one, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, p. e0131177
Antibody drug conjugates (ADCs) have recently been proven to be highly potent anti-tumor drugs, typically exceeding the efficacy of conventional monoclonal... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Cysteine Endopeptidases - chemistry | Staphylococcus aureus - enzymology | Aminoacyltransferases - immunology | Receptor, ErbB-2 - genetics | Humans | Bacterial Proteins - chemistry | Ovarian Neoplasms - pathology | Ki-1 Antigen - immunology | Maytansine - pharmacology | Immunoconjugates - immunology | Immunoconjugates - pharmacology | Antibodies, Monoclonal, Humanized - pharmacology | Protein Engineering | Maytansine - chemistry | Female | Antineoplastic Agents - pharmacology | Bacterial Proteins - immunology | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Oligopeptides - chemistry | Ovarian Neoplasms - drug therapy | Antibodies, Monoclonal - chemistry | Antibodies, Monoclonal - immunology | Aminoacyltransferases - chemistry | Antineoplastic Agents - immunology | Maytansine - analogs & derivatives | Antibodies, Monoclonal - pharmacology | Oligopeptides - immunology | Antineoplastic Agents - chemistry | Immunoconjugates - chemistry | Staphylococcus aureus - chemistry | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Ki-1 Antigen - antagonists & inhibitors | Mice | Antibodies, Monoclonal, Humanized - immunology | Cysteine Endopeptidases - immunology | Maytansine - immunology | Trastuzumab | Antibodies, Monoclonal, Humanized - chemistry | Ki-1 Antigen - genetics | Ovarian Neoplasms - immunology | Monoclonal antibodies | Enzymes | Cysteine | Peptides | Biopharmaceutics | Drugs | Conjugates | Addition polymerization | Ovarian carcinoma | Clinical trials | Pentaglycine | Cancer therapies | Molecular weight | Ovarian cancer | Proteins | Tubulin | CD30 antigen | Xenografts | Medical research | Immunoglobulins | Polypeptides | Cloning | Polymerization | Breast cancer | ErbB-2 protein | Substrates | Chemotherapy | Lysine | Heavy chains | Toxins | Conjugation | Sortase | Tumors
Journal Article
Molecular immunology, ISSN 0161-5890, 04/2012, Volume 50, Issue 4, pp. 200 - 209
Journal Article